Clinical trials: Elderly Infection
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older .
- Trial name
- NCT06678607
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, PPSV23
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Influenza
Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza
To demonstrate that the efficacy over a defined surveillance period against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in adults aged at…
- Trial name
- FluMist (NCT00192413)
- Testing
- Cold-adapted influenza vaccine trivalent (CAIV-T), Trivalent Inactivated Vaccine (TIV)
- Where
- 4 sites in South Africa
- Volunteers
- 3,009 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Staphylococcal Infections
Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
The purpose of this study is to evaluate the safety and immunogenicity of a single vaccination of an investigational vaccine against Staphylococcus aureus (SA4Ag) in healthy adults aged 18 to <65 years.
- Trial name
- NCT02364596
- Testing
- SA4Ag vaccine, Blood sample
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer
AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
This is a first in human testing of novel HIV-1 protein nanoparticles vaccine candidates, UVAX-1107 and UVAX-1197 mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants.
- Conditions
- AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases, HIV Infections
- Trial name
- NCT06541093
- Testing
- UVAX-1107, UVAX-1197
- Where
- Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Uvax Bio LLC
Influenza
Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of an adjuvanted influenza vaccine in elderly subjects.
- Trial name
- NCT00316628
- Testing
- influenza vaccine
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Novartis
Pneumonia, Pneumococcal
Study of Gamma PN3 in the Elderly
Phase 1 double- blind randomised active comparator dose escalating study of Gamma PN3 in the elderly
- Trial name
- NCT06562790
- Testing
- Gamma PN3, Prevnar
- Where
- Australia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Seasonal Influenza, Vaccine
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009
Annual trial for registration influenza vaccine with the strain composition for season 2008/2009
- Trial name
- NCT00735410
- Testing
- Seasonal Influenza Vaccine
- Where
- Germany
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pneumonia
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years
The goal of this clinical trial is to learn about persistence of immunity of PCV13 in healthy population aged 2 months, 7 months-5 years.
- Trial name
- NCT06210737
- Testing
- PCV13
- Where
- China
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Herpes Zoster
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland.
- Trial name
- NCT07502560
- Testing
- Recombinant zoster vaccine
- Where
- 8 sites in Finland
- Volunteers
- 33,609 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Swine-Origin A/H1N1 Influenza Virus
Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults
This study is designed to assess the safety of the approved and licensed HUMENZA (adjuvanted A/H1N1 pandemic influenza vaccine) and PANENZA (non-adjuvanted A/H1N1 pandemic influenza vaccine) to meet regulatory requirements for…
- Trial name
- NCT01032980
- Where
- 5 sites in France
- Volunteers
- 3,934 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Papillomavirus
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV…
- Trial name
- NCT00552279
- Testing
- Cervarix TM
- Where
- 16 sites in Italy, Romania and 1 more
- Volunteers
- 805 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bronchiolitis
PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)
The purpose of this study is to look at the preliminary safety profile of an investigational drug in children 3 to 6 months of age with bronchiolitis.
- Trial name
- NCT00394069
- Testing
- MK-0476, montelukast sodium
- Volunteers
- 14 people
- Sponsor
- Organon and Co
HIV-1 Infection
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
The primary objective of this study is to evaluate the safety of elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone…
- Trial name
- NCT02616783
- Testing
- E/C/F/TAF, TDF, FTC
- Where
- 35 sites in Belgium, France and 3 more
- Volunteers
- 167 people
- Sponsor
- Gilead Sciences
COVID-19
Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years
This is an open-labelled, bridging phase Ⅲ clinical trial of COVID-19 Vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05137418
- Testing
- COVID-19 Vaccine,Inactivated
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Influenza
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
This is an open study of the use of AdimFlu-V (2012-2013 season) vaccine in non-elderly and elderly subjects. All participates will receive one dose of vaccine (0.5 ml) by intramuscular injection into the upper arm.
- Trial name
- NCT01759654
- Testing
- AdimFlu-V
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
COVID-19
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
SCTV01C-02-1 is a randomized, double-blind, placebo controlled Phase Ⅰ/Ⅱ clinical trial of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant bivalent trimeric S protein vaccine manufactured by…
- Trial name
- NCT05148091
- Testing
- SCTV01C, Adjuvant, Saline
- Where
- 5 sites in China
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Lyme Borreliosis
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study conducted in two study phases: a run-in phase and a main study phase.
- Trial name
- NCT03769194
- Testing
- VLA15
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 572 people, healthy volunteers welcome
- Sponsor
- Pfizer
Encephalitis, Tick-borne
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in…
- Trial name
- NCT00161746
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
- Trial name
- NCT05071313
- Testing
- Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine
- Where
- 19 sites in United States
- Volunteers
- 777 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years
This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05112913
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
- Where
- China
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.